lifestyle.fictiontalk.com

Author: Verismo Therapeutics

Verismo Therapeutics’ Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session

April 20, 2026
Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development

April 15, 2026
Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data – Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 – at AACR Annual Meeting 2026

March 17, 2026
Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR-T

December 9, 2025
Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings

November 8, 2025
Verismo Therapeutics to Present at iMig 2025

October 24, 2025